Arcus Biosciences Inc RCUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
-
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
-
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
-
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences Announces New Employment Inducement Grants
-
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
-
Arcus Biosciences Announces New Employment Inducement Grants
Trading Information
- Previous Close Price
- $19.36
- Day Range
- $18.43–19.09
- 52-Week Range
- $16.41–31.74
- Bid/Ask
- $18.15 / $19.00
- Shares Outstanding
- 127.33M
- Market Cap
- $2.36B
- Volume/Avg
- 6M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.87
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 601
- Website
- https://www.arcusbio.com
Valuation
|
Metric
|
RCUS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.08 |
Price/Sales | 18.87 |
Price/Cash Flow | — |
Price/Earnings
RCUS
Financial Strength
|
Metric
|
RCUS
|
|---|---|
Quick Ratio | 3.75 |
Current Ratio | 3.82 |
Interest Coverage | −44.18 |
Quick Ratio
RCUS
Profitability
|
Metric
|
RCUS
|
|---|---|
Return on Assets (Normalized) | −38.85% |
Return on Equity (Normalized) | −76.23% |
Return on Invested Capital (Normalized) | −66.87% |
Return on Assets
RCUS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|VfQ^??< | LOCK|>%yT | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|qVmw>m | LOCK|$>?@ | $83B | |||
| Moderna Inc
MRNA
| LOCK|T!?r&<h | LOCK|Z^ | $80B | |||
| argenx SE ADR
ARGX
| LOCK|!LDB>Zy | LOCK|^F | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Z&W#>R< | LOCK|@Nr | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|D!vvT#! | LOCK|B?$Kn | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<&FY!j@H | LOCK|QN&T# | $28B | |||
| Incyte Corp
INCY
| LOCK|#S^crdG | LOCK|Z>v | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^^>x$>c | LOCK|$<& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?<&!xr | LOCK|$!? | $14B |
United States